Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · IEX Real-Time Price · USD
2.430
-0.110 (-4.33%)
May 2, 2024, 2:47 PM EDT - Market closed

Innate Pharma Revenue

In the year 2023, Innate Pharma had annual revenue of $68.49M with 11.63% growth.

Revenue (ttm)
$68.49M
Revenue Growth
+11.63%
P/S Ratio
2.82
Revenue / Employee
$382,626
Employees
179
Market Cap
196.45M USD

Revenue Chart

* The company reports in EUR currency but revenue data is shown in USD.

History

Fiscal Year End Revenue Change Growth
Dec 31, 202368.49M7.13M11.63%
Dec 31, 202261.36M33.28M118.57%
Dec 31, 202128.07M-57.02M-67.01%
Dec 31, 202085.09M-10.92M-11.37%
Dec 31, 201996.01M-11.98M-11.09%
Dec 31, 2018107.99M55.15M104.37%
Dec 31, 201752.84M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Auna S.A. 1.04B
Lifecore Biomedical 103.27M
Zevra Therapeutics 27.46M
uniQure 15.84M
Lineage Cell Therapeutics 8.95M
Century Therapeutics 2.24M
Cardiff Oncology 488.00K
Revenue Rankings